Results 201 to 210 of about 59,853 (261)

Anti‐PD‐1 Nanobody‐Armored MSLN CAR‐T Therapy for Malignant Mesothelioma: Preclinical and Clinical Studies

open access: yesAdvanced Science, EarlyView.
A novel therapy using engineered immune cells (NAC‐T cells) showed promise for refractory malignant mesothelioma. Based on the encouraging preclinical data, the first‐in‐human trial is initiated, demonstrating tolerable safety and promising anti‐tumor activity (ORR 63.6%, DCR 100%, including one CR).
Yan Sun   +23 more
wiley   +1 more source

A Patient‐Derived Organ‐on‐Chip Platform for Modeling the Tumor Microenvironment and Drug Responses in Pancreatic Cancer

open access: yesAdvanced Science, EarlyView.
Researchers have developed a patient‐derived organ‐on‐a‐chip model for pancreatic cancer by integrating cancer cells with supportive stromal and immune cells inside a microfluidic device. This system mimics the tumor microenvironment, enabling personalized testing of chemotherapy and immunotherapy, and offering new insights into how targeting ...
Darbaz Adnan   +11 more
wiley   +1 more source

Wedelolactone, a Novel TLR2 Agonist, Promotes Neutrophil Differentiation and Ameliorates Neutropenia: A Multi‐Omics Approach to Unravel the Mechanism

open access: yesAdvanced Science, EarlyView.
Wedelolactone (WED), a natural TLR2 agonist, promotes neutrophil differentiation and enhances bactericidal function, offering a potential therapeutic strategy for neutropenia. Using a multi‐omics approach, this study reveals that WED activates the TLR2/MEK/ERK pathway, upregulating key transcription factors (PU.1, CEBPβ) to drive neutrophil development.
Long Wang   +16 more
wiley   +1 more source

Design and Implementation of a Multi-Mode Telemetry Transmitter. [PDF]

open access: yesSensors (Basel)
Silino F   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy